. 2019 Mar 12;10(21):2030–2040. doi: 10.18632/oncotarget.26771

Table 2. Clinicopathologic characteristics of DLBCL patients.

Characteristic		All patients	TIM3 low	TIM3 high	P
Gender (n)	Male	32	24	8	0.20^*
	Female	38	23	15	0.20^*
Median Age (yrs)		69	70	68	0.47^#
Performance Status (n)	0–1	35	24	11	0.08^*
	2+	17	11	6	0.08^*
	NA	18
Stage (n)	1-2	28	21	7	0.22^*
	3-4	38	23	15	0.22^*
	NA	4
IPI Score (n)	0-2	33	26	7	0.02^*
	3+	24	12	12	0.02^*
	NA	13
Treatment (n)	R-CHOP	45	31	14	0.68^*
	Other	25	16	9	0.68^*

^*Chi-square test.

^#t-test.

Abbreviations: TIM-3, T cell immunoglobulin and mucin domain-containing protein-3; n, number; yrs, years; GCB, germinal center; NA, not available; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, oncovin, prednisone.